The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Parkinson's disease: a dual‐hit hypothesis
Open accessAbstract
Accumulating evidence suggests that sporadic Parkinson's disease has a long prodromal period during which several non-motor features develop, in particular, impairment of olfaction, vagal dysfunction and sleep disorder. Early sites of Lewy pathology are the olfactory bulb and enteric plexus of the stomach. We propose that a neurotropic pathogen, probably viral, enters the brain via two routes: (i) nasal, with anterograde progression into the temporal lobe; and (ii) gastric, secondary to swallowing of nasal secretions in saliva. These secretions might contain a neurotropic pathogen that, after penetration of the epithelial lining, could enter axons of the Meissner's plexus and, via transsynaptic transmission, reach the preganglionic parasympathetic motor neurones of the vagus nerve. This would allow retrograde transport into the medulla and, from here, into the pons and midbrain until the substantia nigra is reached and typical aspects of disease commence. Evidence for this theory from the perspective of olfactory and autonomic dysfunction is reviewed, and the possible routes of pathogenic invasion are considered. It is concluded that the most parsimonious explanation for the initial events of sporadic Parkinson's disease is pathogenic access to the brain through the stomach and nose - hence the term 'dual-hit'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The double-hit hypothesis proposed by Hawkes et al.135 supports their theory, pointing out that a-synuclein pathology is transmitted to the midbrain through two different routes, namely, from the nasal cavity to the temporal lobe or from the stomach, followed by nasal secretions in swallowed saliva.135”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [135]
Experimental — accuracy not yet measuredIn the citing paper
“Conversely, when the α-synuclein pathology firstly occurred in the olfactory bulbs, it spread further to the brain via the olfactory tract but it also went down to the ENS and it damaged its neurons [402].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [402]
In the citing paper
“Braak and colleagues hypothesized that alpha-synuclein pathology might start in either the OB and/or in the ENS possibly by an unknown pathogen and/or environmental toxin and then progresses towards the SN and further areas in the CNS.”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Hawkes et al., 2007
In the citing paper
“The vagal nerve might provide a path for the spread of alpha-synuclein pathology from the ENS to the brain through the brainstem, midbrain, basal forebrain and finally the cortical areas (Braak et al., 2003;Hawkes et al., 2007)”
From The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies (2017) · cites this paper as Hawkes et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Self-citationHummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997) · Chemical Senses · doi:10.1093/chemse/22.1.39 · Cited by 2,501
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Self-citationPaxinos, G., & Jürgen, K. (2004) · Cited by 1,478
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Self-citationSchenck, C. H., Bundlie, S. R., & Mahowald, M. W. (1996) · Neurology · doi:10.1212/wnl.46.2.388 · Cited by 1,083
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Research works printed but not linked: 4
- Braak H, 2005, Parkinson's Disease: Progress in Research., 1
- Sulla M, 1996, Gastric emptying time and gastric motility in patients with untreated Parkinson's disease, Mov Disord, 11, 1041
- Schenck CH, 2003, REM behavior disorder (RBD), delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum & maximum tonic and/or phasic electromyographic abnormalities found during REM sleep, Sleep, 26, 316
- 10.1042/bse0410139 · DOI
Cited by
Sorted by citations
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281
Unger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Prion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome
Zhou, J., Gennatas, E. D., Kramer, J. H., Miller, B. L., & Seeley, W. W. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.004 · Cited by 706
the Arizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Lue, L., Sue, L. I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0538-8 · Cited by 698
Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Appel‐Cresswell, S., Vilariño‐Güell, C., Encarnacion, M. J., Sherman, H. E., Yu, I. S., Shah, B., Weir, D., Thompson, C., Szu‐Tu, C., Trinh, J., et al. (2013) · Movement Disorders · doi:10.1002/mds.25421 · Cited by 687
Colonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
A timeline for Parkinson's disease
Hawkes, C. H., Del Tredici, K., & Braak, H. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2009.08.007 · Cited by 594
Self-citationThe gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Brain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Saxena, S., & Caroni, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.031 · Cited by 578
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
Kouli, A., Torsney, K., & Kuan, W. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 634
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554
The outdoor air pollution and brain health workshop
Block, M. L., Elder, A., Auten, R. L., Bilbo, S. D., Chen, H., Chen, J.-C., Cory-Slechta, D. A., Costa, D., Diaz-Sanchez, D., Dorman, D. C., et al. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.08.014 · Cited by 539
The gut microbiome in human neurological disease: A review
Tremlett, H., Bauer, K. C., Appel‐Cresswell, S., Finlay, B. B., & Waubant, E. (2017) · Annals of Neurology · doi:10.1002/ana.24901 · Cited by 535
The microbiome of the upper respiratory tract in health and disease
Kumpitsch, C., Koskinen, K., Schöpf, V., & Moissl‐Eichinger, C. (2019) · BMC Biology · doi:10.1186/s12915-019-0703-z · Cited by 490
Parkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · FEBS Journal · doi:10.1111/febs.14607 · Cited by 483
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 461
Medical records documentation of constipation preceding Parkinson disease
Savica, R., Carlin, J. M., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Bharucha, A. E., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34af5 · Cited by 431
Lebouvier, T., Neunlist, M., Bruley des Varannes, S., Coron, E., Drouard, A., N'Guyen, J.-M., Chaumette, T., Tasselli, M., Paillusson, S., Flamand, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012728 · Cited by 427
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Review: Sporadic Parkinson's disease: development and distribution ofα‐synuclein pathology
Tredici, K. D., & Braak, H. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 416
Self-citationExploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
The olfactory vector hypothesis of neurodegenerative disease: Is it viable?
Doty, R. L. (2008) · Annals of Neurology · doi:10.1002/ana.21327 · Cited by 391
Parkinson’s disease: The non-motor issues
Chaudhuri, К. R., Odin, P., Antonini, A., & Martínez‐Martín, P. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.02.018 · Cited by 390
Role of microbiota-derived short-chain fatty acids in nervous system disorders
Mirzaei, R., Bouzari, B., Hosseini‐Fard, S. R., Mazaheri, M., Ahmadyousefi, Y., Abdi, M., Jalalifar, S., Karimitabar, Z., Teimoori, A., Keyvani, H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111661 · Cited by 408
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Self-citationLiu, A. K. L., Chang, R. C., Pearce, R. K. B., & Gentleman, S. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1392-5 · Cited by 365
Chen, Z., Li, G., & Liu, J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 364
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361
Multiple organ involvement by alpha-synuclein pathology in lewy body disorders
Gelpi, E., Navarro‐Otano, J., Tolosa, E., Gaig, C., Compta, Y., Rey, M. J., Martí, M. J., Hernández, I., Valldeoriola, F., Reñé, R., et al. (2014) · Movement Disorders · doi:10.1002/mds.25776 · Cited by 361
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346
Hilton, D., Stephens, M., Kirk, L., Edwards, P., Potter, R., Zajicek, J., Broughton, E., Hagan, H., & Carroll, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1214-6 · Cited by 345
Johnson, M., & Bobrovskaya, L. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 344
Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., & Takahashi, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0257-5 · Cited by 328
CD4+ Regulatory and Effector/Memory T Cell Subsets Profile Motor Dysfunction in Parkinson’s Disease
Hutter-Saunders, J. A. L., Estes, K. A., Kosloski, L. M., Allen, H. E., Dempsey, K., Torres‐Russotto, D. R., Meza, J. L., Santamaria, P. M., Bertoni, J. M., Murman, D. L., et al. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9402-z · Cited by 339
Danzer, K. M., Ruf, W. P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C. C., Hyman, B. T., & McLean, P. J. (2010) · The FASEB Journal · doi:10.1096/fj.10-164624 · Cited by 326
Parkinson's Disease: The Dual Hit Theory Revisited
Hawkes, C. H., Del Tredici, K., & Braak, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04365.x · Cited by 303
Self-citationContributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Jang, H., Boltz, D. A., Webster, R. G., & Smeyne, R. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.001 · Cited by 298
Human gut microbiota: the links with dementia development
Alkasir, R., Li, J., Li, X., Jin, M., & Zhu, B. (2016) · Protein & Cell · doi:10.1007/s13238-016-0338-6 · Cited by 289
Are synucleinopathies prion-like disorders?
Angot, E., Steiner, J. A., Hansen, C., Li, J.-Y., & Brundin, P. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70213-1 · Cited by 251
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
The vermiform appendix impacts the risk of developing Parkinson’s disease
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N. L., Haas, A. J., Vepa, Y., Lindqvist, D., Chen, H., Thomas, P. M., Brundin, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5280 · Cited by 287
The prion hypothesis in Parkinson's disease: braak to the future
Visanji, N. P., Brooks, P. L., Hazrati, L.-N., & Lang, A. E. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-2 · Cited by 278
Diffusion tensor imaging in Parkinson's disease: Review and meta-analysis
Atkinson-Clément, C., Pinto, S., Eusébio, A., & Coulon, O. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.07.011 · Cited by 277
Prying into the Prion Hypothesis for Parkinson's Disease
Brundin, P., & Melki, R. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1788-16.2017 · Cited by 293
Emerging technologies for improved deep brain stimulation
Cagnan, H., Denison, T., McIntyre, C. C., & Brown, P. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0244-6 · Cited by 274
Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice
Rey, N. L., Petit, G. H., Bousset, L., Melki, R., & Brundin, P. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1160-3 · Cited by 277
The second brain and Parkinson’s disease
Lebouvier, T., Chaumette, T., Paillusson, S., Duyckaerts, C. J., Varannes, S. B. D., Neunlist, M., & Derkinderen, P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06873.x · Cited by 271
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology
Drolet, R. E., Cannon, J. R., Montero, L. M., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.017 · Cited by 262
Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause?
Muddapu, V. R., Dharshini, S. A. P., Chakravarthy, V. S., & Gromiha, M. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00213 · Cited by 255
Uchihara, T., & Giasson, B. I. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1485-1 · Cited by 249
The Olfactory System and Its Disorders
Doty, R. L. (2009) · Seminars in Neurology · doi:10.1055/s-0028-1124025 · Cited by 242
Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?
Tomé, C. M. L., Tyson, T., Rey, N. L., Grathwohl, S. A., Britschgi, M., & Brundin, P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8267-8 · Cited by 247
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders
Jellinger, K. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.006 · Cited by 247
A critical reappraisal of current staging of Lewy-related pathology in human brain
Jellinger, K. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0406-y · Cited by 240
The Microbiome as a Modifier of Neurodegenerative Disease Risk
Fang, P., Kazmi, S. A., Jameson, K. G., & Hsiao, E. Y. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.008 · Cited by 226
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Review article What causes alzheimer’s disease?
Armstrong, R. A. (2013) · Folia Neuropathologica · doi:10.5114/fn.2013.37702 · Cited by 237
Environmental Exposures and Parkinson’s Disease
Nandipati, S., & Litvan, I. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13090881 · Cited by 219
Neuropathological evidence of body-first vs. brain-first Lewy body disease
Borghammer, P., Horsager, J., Andersen, K. B., Berge, N. V. D., Raunio, A., Murayama, S., Parkkinen, L., & Myllykangas, L. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105557 · Cited by 237
Reverse engineering Lewy bodies: how far have we come and how far can we go?
Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 205
Oral and nasal microbiota in Parkinson's disease
Pereira, P. A. B., Aho, V. T. E., Paulin, L. G., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.026 · Cited by 211
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
“…pathology from the ENS to the brain through the brainstem, midbrain, basal forebrain and finally the cortical areas (Braak et al., 2003; Hawkes et al., 2007), whereas the initiation of the pathological process in the OB can more directly affect the brain via the olfactory tract (Hawkes…”
BackgroundParkinson's disease and α‐synuclein expression
Devine, M. J., Gwinn, K. A., Singleton, A., & Hardy, J. (2011) · Movement Disorders · doi:10.1002/mds.23948 · Cited by 207
Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade
Marras, C., Canning, C. G., & Goldman, S. M. (2019) · Movement Disorders · doi:10.1002/mds.27720 · Cited by 199
Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 212
Phillips, R. J., Walter, G. C., Wilder, S. L., Baronowsky, E. A., & Powley, T. L. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.074 · Cited by 189
Parkinson's Disease Is Not Simply a Prion Disorder
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1787-16.2017 · Cited by 197
Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management
Warnecke, T., Schäfer, K., Claus, I., Tredici, K. D., & Jost, W. H. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00295-x · Cited by 200
Huang, B., Chau, S. W. H., Liu, Y., Chan, J. W. Y., Wang, J., Ma, S. L., Zhang, J., Chan, P. K. S., Yeoh, Y. K., Chen, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38248-4 · Cited by 187
Lewy pathology and neurodegeneration in premotor Parkinson's disease
Tredici, K. D., & Braak, H. (2012) · Movement Disorders · doi:10.1002/mds.24921 · Cited by 187
Self-citationGorecki, A. M., Preskey, L., Bakeberg, M. C., Kenna, J. E., Gildenhuys, C., MacDougall, G., Dunlop, S. A., Mastaglia, F. L., Akkari, P. A., Koengten, F., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00839 · Cited by 184
The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review
Klann, E. M., Dissanayake, U., Gurrala, A., Farrer, M. J., Shukla, A. W., Ramirez‐Zamora, A., Mai, V., & Vedam‐Mai, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.782082 · Cited by 198
The concept of alpha-synuclein as a prion-like protein: ten years after
Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2814-1 · Cited by 183
Parkinson's Disease: A Multisystem Disorder
Costa, H. N., Esteves, A. R., Empadinhas, N., & Cardoso, S. M. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00934-6 · Cited by 205
Neurotoxicity of Metal Mixtures
Andrade, V. M., Aschner, M., & dos Santos, A. P. M. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-60189-2_12 · Cited by 180
Frigerio, R., Fujishiro, H., Ahn, T. B., Josephs, K. A., Maraganore, D. M., DelleDonne, A., Parisi, J. E., Klos, K. J., Boeve, B. F., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.019 · Cited by 172
Preclinical Biomarkers of Parkinson Disease
Wu, Y., Le, W., & Jankovic, J. J. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.321 · Cited by 173
Synaptic failure and α‐synuclein
Calò, L., Węgrzynowicz, M., Santivañez‐Perez, J., & Spillantini, M. G. (2016) · Movement Disorders · doi:10.1002/mds.26479 · Cited by 179
Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection
Méndez-Guerrero, A., Laespada-García, M. I., Gómez‐Grande, A., Ruiz-Ortiz, M., Blanco-Palmero, V. A., Azcárate-Díaz, F. J., Suárez, P. R., Álvarez-Torres, E., de la Hoz, C. P. D. F., Pérez, D. V., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010282 · Cited by 169
Biological links between traumatic brain injury and Parkinson’s disease
Delic, V., Beck, K. D., Pang, K. C. H., & Citron, B. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00924-7 · Cited by 165
Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy
Valdinocci, D., Radford, R. A. W., Goulding, M., Hayashi, J., Chung, R. S., & Pountney, D. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124129 · Cited by 161
Wakabayashi, K., Mori, F., Tanji, K., Orimo, S., & Takahashi, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0706-x · Cited by 162
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
Berg, D., Lang, A. E., Postuma, R. B., Maetzler, W., Deuschl, G., Gasser, T., Siderowf, A. D., Schapira, A. H. V., Oertel, W. H., Obeso, J. A., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70047-4 · Cited by 164
Metadata
- Authors
- Hawkes, C. H., Del Tredici, K., & Braak, H.
- Affiliations
- Queen's Hospital (GB)
- Goethe University Frankfurt (DE)
- Corresponding author
- Hawkes, C. H.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2007-10-24
- Volume
- 33
- Issue
- 6
- Pages
- 599-614
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- PMC
- PMC7194308
- OpenAlex
- W2105047187
- Cited by
- 1,021
- References
- 163
- Citations by year
- 2026: 35 · 2025: 59 · 2024: 87 · 2023: 82 · 2022: 104 · 2021: 117 · 2020: 83 · 2019: 59 · 2018: 49 · 2017: 63 · 2016: 41 · 2015: 33 · 2014: 32 · 2013: 40 · 2012: 33
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuropathology and Applied Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Parkinson's disease, neurotropic viruses, olfactory dysfunction, Lewy bodies, vagal dysfunction, sleep disorder, olfactory bulb, submucosal plexus, vagus nerve, substantia nigra, prodromal Parkinson's disease, viral pathogenesis
- MeSH terms
- Animals, Olfaction Disorders, Gastrointestinal Diseases, Heart Diseases, Humans, Models, Neurological, Parkinson Disease, Sleep Wake Disorders, Virus Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
